Synergistic Combinations for Corneal Endothelial Disease Treatment and Management
Legal Citation
Summary of the Inventive Concept
A novel system integrating (T)EW-7197 with AI, IoT, blockchain, and new materials to provide a more effective and personalized treatment and management approach for corneal endothelial diseases
Background and Problem Solved
The original patent disclosed the use of (T)EW-7197 for treating or preventing corneal endothelial diseases. However, it had limitations in terms of tracking, monitoring, and personalizing treatment. The new inventive concept addresses these limitations by integrating (T)EW-7197 with distinct technologies to create a more powerful system
Detailed Description of the Inventive Concept
The new inventive concept comprises a pharmaceutical composition including (T)EW-7197, which is integrated with a blockchain-based tracking module, a wearable device for monitoring corneal endothelial cell density, and machine learning algorithms for predicting treatment efficacy. Additionally, the system incorporates a deep learning-based image analysis module, an AI-powered decision support system, and a decentralized IoT network for real-time monitoring. The system also enables personalized treatment through 3D-printed customized corneal implants with micro-sensors for real-time monitoring
Novelty and Inventive Step
The new claims introduce the synergistic combination of (T)EW-7197 with AI, IoT, blockchain, and new materials, which provides a non-obvious and novel solution for treating and managing corneal endothelial diseases
Alternative Embodiments and Variations
Alternative embodiments may include integrating the system with electronic health records, using different types of wearable devices, or incorporating additional AI-powered analytics modules. Variations may include using different pharmaceutical compositions or adapting the system for other ocular diseases
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in the ophthalmology industry, particularly in the areas of personalized medicine, disease management, and medical device development. Target industries may include pharmaceutical companies, medical device manufacturers, and healthcare providers
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Medical biotechnology, pharmaceutical compositions, ophthalmology, specifically corneal endothelial disease treatment and diagnostic technologies
Person of Ordinary Skill (PHOSITA) Profile
A medical researcher or biotechnology professional with advanced degrees in pharmaceutical sciences, biomedical engineering, or clinical ophthalmology, possessing expertise in drug development, medical device integration, and digital health technologies
Obviousness Rationale
A PHOSITA would recognize that integrating digital monitoring technologies with pharmaceutical treatments represents a predictable evolution of personalized medical care. The combination of (T)EW-7197 with AI, IoT, and blockchain tracking systems follows established trends in precision medicine and digital health interventions. The proposed variations represent logical extensions of existing medical technology integration strategies that would be apparent to a skilled practitioner seeking enhanced treatment monitoring and personalization.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,544 |
|---|---|
| Title | Composition or method including (t)ew-7197 for treating or preventing corneal endothelial diseases |
| Assignee(s) | SENJU PHARMACEUTICAL CO., LTD., THE DOSHISHA |